Cryo-Cell International, Inc. reported a significant increase in profitability for the fiscal third quarter ended August 31, 2026. Net income rose to $1.27 million, or $0.16 per basic and diluted share, compared to $749,000 in the corresponding period last year.

Consolidated revenues held steady at $7.82 million, showing negligible change from the $7.83 million recorded in Q3FY25. This stability in the top line, coupled with a substantial jump in bottom-line earnings, suggests improved operational efficiency or cost management during the quarter.

Financial Performance Overview

The company's financial results for the three months ended August 31, 2026, highlight a divergence between flat revenue growth and robust profit expansion. The following table summarizes the key metrics:

What the Numbers Show

A clear pattern emerges when comparing revenue stability against profit growth. While consolidated revenues contracted marginally by $10,000 year-over-year, net income expanded by approximately $521,000. This indicates that the increase in earnings was not driven by volume or price-led revenue growth, but rather by factors internal to the company’s cost structure or non-operating items not detailed in this summary. The earnings per share (EPS) also saw a notable improvement, rising from $0.09 to $0.16.

Company Profile

Founded in 1989, Cryo-Cell International is recognized as the world’s first private cord blood bank. The company stores over 250,000 cord blood and cord tissue specimens globally. Its public banking program, in partnership with Duke University, has facilitated more than 900 transplants. The facility is FDA-registered and holds FACT accreditation, distinguishing it as the first U.S. private family-use cord blood bank to achieve this standard.

Cryo-Cell International, Inc. reported fiscal second quarter results for the period ended May 31, 2026, revealing a 56% increase in net income to $555,000, or $0.07 per basic and diluted share, compared to $356,000, or $0.04 per share, in the prior year. Despite the profitability surge, total revenue declined 2% to $7.8 million from $7.9 million in the second quarter of fiscal 2025, highlighting a divergence between top-line performance and bottom-line growth.

Financial Performance

The company's revenue stream was primarily driven by processing and storage fee revenue, which totaled $7.71 million for the quarter, down from $7.87 million in the same period last year. Public banking revenue increased to $46,000 from $43,000, while product revenue remained flat at $14,000 year-over-year.

Quarterly Comparison

The financial results indicate that while operational efficiency or cost management bolstered earnings, the company faced headwinds in generating sales growth during the quarter. Cryo-Cell International, Inc. operates as the world’s first private cord blood bank, storing more than 250,000 cord blood and cord tissue specimens globally.